Exploring protein kinase inhibitors: Unveiling gemcitabine resistance in pancreatic cancer

Pancreas

Volumn 41, Issue 5, 2012, Pages 804-805

  Kim, Yeon Jeong ^a   Hong, Young Bin ^a,b   Cho, Chi Heum ^c   Seong, Yeon Sun ^b   Bae, Insoo ^a,b  

^a Dankook University   (South Korea)

^b GEORGETOWN UNIVERSITY   (United States)

^c Keimyung University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALISERTIB; AURORA KINASE INHIBITOR; BARASERTIB; BML 275; CHIR 99021; DANUSERTIB; DASATINIB; DNA; EVEROLIMUS; GEMCITABINE; GSK 1059615; INDIRUBIN; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NSC 109555; NU 7441; PD 407824; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; RIDAFOROLIMUS; SB 218078; TCS 2312; UNCLASSIFIED DRUG; WYE 354;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN; CELL SURVIVAL; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; GENOTOXICITY; IN VITRO STUDY; LETTER; MITOSIS; MITOSIS SPINDLE; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84863636114     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823f3fcb     Document Type: Letter

References (10)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
2. Nishio R, Tsuchiya H, Yasui T, et al. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Sci. 2011;102:622-629.
3. Hong YB, Kim JS, Yi YW, et al. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. Pancreas. 2011;41:496-498.
4. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.
5. Schlieman MG, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated Akt in pancreas cancer. Br J Cancer. 2003;89:2110-2115.
6. Azorsa DO, Gonzales IM, Basu GD, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med. 2009;7:43.
7. Duxbury MS, Ito H, Zinner MJ, et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10:2307-2318.
8. Mamaghani S, Patel S, Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009;9:132.
9. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547-566.
10. Azzariti A, Bocci G, Porcelli L, et al. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer. 2011;104:769-780.